Early phase I data on lutetium (177Lu) rhPSMA-10.1 for the treatment of metastatic castration-resistant prostate cancer (mCRPC) has demonstrated an encouraging safety profile for the novel radioligand therapy. Developed by Blue Earth Therapeutics Ltd, 177Lu rhPSMA-10.1 was administered to patients in the phase I trial in July. Radiation dosimetry that was conducted for up to 3 cycles revealed high radiation doses absorbed by the tumor relative to the dose received by key normal organs, including the kidneys and salivary glands. ...
Prostate Cancer
Advertisement
Latest News
In the final segment of our roundtable series, the panelists discuss the treatment of CRPC, focusing on metastatic disease.
In the fifth segment of our roundtable series, the treatment of patients with CRPC is discussed.
In the fourth part of our series, the panelists discuss PROs and potential patient comorbidities.
In the third part of this series, disparities and the optimization of care is discussed, along with the use of ADT and ARPIs.
In the second segment of our roundtable series, the panelists discuss their approaches to the use of PSMA PET for patients.
In the first part of this series, the panel discusses treatments in the post-salvage setting and review therapeutic options.
Advertisement
Conference Coverage
AUC3 will drive consensus on clinical guidelines that are vague about advanced kidney and bladder cancer treatments.
In the final segment of our roundtable series, the panelists discuss the treatment of CRPC, focusing on metastatic disease.
In the fifth segment of our roundtable series, the treatment of patients with CRPC is discussed.
In the fourth part of our series, the panelists discuss PROs and potential patient comorbidities.
In the third part of this series, disparities and the optimization of care is discussed, along with the use of ADT and ARPIs.
In the second segment of our roundtable series, the panelists discuss their approaches to the use of PSMA PET for patients.
Advertisement
Advertisement
Latest News
The NIAGARA study showed significant survival benefits with perioperative durvalumab for patients with MIBC.
AUC3 will drive consensus on clinical guidelines that are vague about advanced kidney and bladder cancer treatments.
In the final segment of our roundtable series, the panelists discuss the treatment of CRPC, focusing on metastatic disease.
© 2024 Mashup Media, LLC, a Formedics Property. All Rights Reserved.